INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,014,496 | -35.3% | 480,273 | -21.4% | 0.02% | -33.3% |
| Q2 2023 | $38,676,860 | -7.8% | 610,915 | -21.1% | 0.02% | -14.3% |
| Q1 2023 | $41,936,959 | +176.5% | 774,540 | +170.2% | 0.03% | +154.5% |
| Q4 2022 | $15,167,289 | +43.8% | 286,689 | -36.8% | 0.01% | +37.5% |
| Q3 2022 | $10,550,540 | -1.7% | 453,482 | +141.1% | 0.01% | +14.3% |
| Q2 2022 | $10,731,000 | +38.1% | 188,051 | +48.1% | 0.01% | +75.0% |
| Q1 2022 | $7,772,000 | +0.5% | 127,001 | -14.1% | 0.00% | +33.3% |
| Q4 2021 | $7,730,000 | +42.0% | 147,866 | +1.2% | 0.00% | +50.0% |
| Q3 2021 | $5,445,000 | +1.0% | 146,165 | +10.7% | 0.00% | 0.0% |
| Q2 2021 | $5,391,000 | +35.3% | 132,085 | +12.7% | 0.00% | 0.0% |
| Q1 2021 | $3,984,000 | +167.6% | 117,223 | +150.6% | 0.00% | +100.0% |
| Q4 2020 | $1,489,000 | +169.7% | 46,783 | +33.7% | 0.00% | – |
| Q3 2017 | $552,000 | +26.9% | 35,000 | 0.0% | 0.00% | – |
| Q2 2017 | $435,000 | – | 35,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |